PubMed Health⌕ Search

Biomedical subjects

F Massolo

Publications and source records attributed to F Massolo.

65 records · Page 4Linked to original sources
PubMedDate not supplied

Recombinant growth hormone treatment in short patients with thalassemia major: results after 24 and 36 months.

Treatment with recombinant growth hormone (rhGH), 0.6 IU/kg/week s.c., previously successfully conducted for one year, was continued in 15 (Group A) and 8 (Group B) short thalassemia major patients with reduced GH reserve, for two and three years, respectively. In Group A, height for chronological age (Ht SDSCA) increased significantly (p = 0.021) from the start of treatment, but the positive effect was only apparent because of the concomitant slight worsening of height for bone age (Ht SDSBA). Median deltaHt SDSCA/deltaHt SDSBA was <1.0 with respect to both the start (0.87) and the end of the first year of rhGH therapy (0.89). IGF-I levels increased significantly (p = 0.043) compared with values both at the start and at the end of the first year of rhGH therapy. In Group B neither Ht SDSCA nor Ht SDSBA differed statistically from starting values, the former having a positive trend and the latter a negative one. Median deltaHt SDSCA/deltaHt SDSBA was 0.92 with respect to the start, and 0.94 with respect to the end of the second year. IGF-I levels increased significantly (p = 0.043) with respect to starting values. Our data show that the encouraging results described from the first year of rhGH treatment did not persist during the second and third years, and we conclude that this is because increase in bone age with continued treatment is equal to, or slightly greater than the height age increase. We propose that patients with thalassemia major with short stature should receive rhGH treatment for only one year, and that more prolonged treatment should be reserved for selected adolescents who have psychological problems due to shortness; for these patients growth acceleration could represent the main goal, even if this leads to a substantially unchanged or slightly decreased final height.

Body Height↗
PubMedDate not supplied

[Idiopathic thrombocytopenic purpura and food allergy: a study on possible correlations].

UNLABELLED: Eight children affected by idiopathic chronic thrombocytopenia were studied for history of food allergy, anti-platelet antibodies, total IgE, prick test for food antigens, AGA and EMA. They were free of treatment for thrombocytopenia since at least six months before. Three children had in the first year of life intolerance to cow's milk proteins with atopic dermatitis and/or poor growth. None had AGA or EMA positivity. 6/8 had positivity for anti-platelet antibodies. A 15-days oligoantigenic diet was instituted in all of them. Platelet count was unaffected in all but one, in which a sharp increase was noted (from 19x 10(9)/l. to 150x 10(9)/l.). He was a 12-year-old boy with a previous history of cow's milk intolerance and actual skin prick test positivity for casein and lactoglobulin. A one-year follow up for this case was instituted and he was put on two further 15-days periods of oligoantigenic diet, but no change in platelet count was noted any more. CONCLUSION: we were not able to correlate chronic thrombocytopenia to food allergy.

Adolescent↗
PubMedDate not supplied

[Use of high-dose intravenous immunoglobulins in pediatric hematology].

High-dose intravenous immunoglobulin play a critical role in a lot of pediatric hematologic diseases. In our experience we studied the effects of IVIG treatment in 63 children. They all tolerated IVIG preparations in every infusions; no trouble caused the interruption of treatment. The efficacy is evident in immunomediated diseases, most of all ITP, and controlling septic episodes in immunocompromised patients (ALL, AIDS, marrow bone transplantation). An important problem is the cost of preparation; but we may consider that this treatment, for example in ITP, reduces hospitalization for children, necessity of platelets' transfusions, use of steroids and, therefore, their collateral effects. Hence, we assert that the social cost of the management of ITP disease is not higher in children treated with IVIG. Furthermore, short hospitalization for IVIG therapy contributes to accept this disease. It should be advisable to make controlled studies to define with more accuracy the role of this preparation and the modality of its use in the different clinical conditions in which it is employed.

Adolescent↗
PubMedDate not supplied

Primary hypergammaglobulinemic purpura associated with IgG2 deficiency. A case report.

Hypergammaglobulinemic purpura is a rare disease in children. We report a case of a 12 year-old girl with a history of frequent infections. We found the presence of IgG2 deficiency despite polyclonal hypergammaglobulinemia. An IgG subclass determination should be obtained in every child with polyclonal hypergammaglobulinemia and features of immunodeficiency.

Child↗